People: Echo Therapeutics Inc (ECTE.PH)
ECTE.PH on Philadelphia Stock Exchange
0.22USD
10 May 2013
0.22USD
10 May 2013
Price Change (% chg)
$-0.57 (-72.15%)
$-0.57 (-72.15%)
Prev Close
$0.79
$0.79
Open
$0.22
$0.22
Day's High
$0.22
$0.22
Day's Low
$0.21
$0.21
Volume
2,700
2,700
Avg. Vol
49
49
52-wk High
$1.59
$1.59
52-wk Low
$0.21
$0.21
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Patrick Mooney |
43 | 2009 | Chairman of the Board, President, Chief Executive Officer |
Christopher Schnittker |
43 | 2011 | Chief Financial Officer, Treasurer |
Kimberly Burke |
37 | 2011 | Senior Vice President, General Counsel, Secretary |
Robert Doman |
62 | 2013 | Director |
Vincent Enright |
69 | 2008 | Independent Director |
William Grieco |
60 | 2011 | Independent Director |
James Smith |
62 | 2011 | Independent Director |
Biographies
| Name | Description |
|---|---|
Patrick Mooney |
Dr. Patrick T. Mooney, M.D., is Chairman of the Board, President and Chief Executive Officer of Echo Therapeutics, Inc., since June 19, 2009. Dr. Mooney was appointed Chairman of the Board of Directors. Dr. Mooney’s current term of office as Chief Executive Officer, President and Chairman of the Board of Directors expires in 2012 and his term as a director expires in 2014. Dr. Mooney previously served as President, Chief Executive Officer and Director of Echo Therapeutics, Inc. (a privately-held pharmaceutical company prior to its merger with Sontra Medical Corporation) from 2006 to 2007. Prior to joining Echo Therapeutics, Inc., Dr. Mooney was President, Chief Executive Officer and Chairman of Aphton Corporation (NASDAQ: APHT), a biopharmaceutical company, from 2004 to 2006. Dr. Mooney was a Senior Biotechnology Analyst at Thomas Weisel Partners, LLC, a full service merchant banking firm, and a Senior Biotechnology Analyst at Janney Montgomery Scott, LLC, a full services investment banking firm. He graduated from the Jefferson Medical College of Thomas Jefferson University and trained as a surgical resident at Thomas Jefferson University Hospital. Dr. Mooney currently serves on the Board of Directors of Metastat, a cancer therapy company, to which he was appointed in March 2012. From June to September 2010, Dr. Mooney was a member of the Board of Directors of Quantrx Biomedical Corporation, a healthcare diagnostics company. |
Christopher Schnittker |
Mr. Christopher P. Schnittker, CPA has been appointed as the Chief Financial Officer, Treasurer of Echo Therapeutics Inc. Most recently, he served as Vice President – Administration, Corporate Secretary and Chief Accounting Officer of Soligenix, Inc., a publicly-traded biotechnology company, from 2009 to 2011. Prior to that, Mr. Schnittker served as the Senior Vice President and Chief Financial Officer for VioQuest Pharmaceuticals Inc. (2008 to 2009), Micromet Inc. (2006 to 2008), Cytogen Corporation (2003 to 2006), and Genaera Corporation (2000 to 2003), all publicly-traded biotechnology companies. Mr. Schnittker has also held prior financial management positions at GSI Commerce, Rhône-Poulenc Rorer (now part of Sanofi-Aventis), and PricewaterhouseCoopers. He received his B.A. degree in economics and business from Lafayette College and is a certified public accountant licensed in the State of New Jersey. |
Kimberly Burke |
Ms. Kimberly A. Burke serves as the General Counsel, Senior Vice President and Secretary of Echo Therapeutics Inc. She was appointed as General Counsel and Senior Vice President of the Company in January 2011 and she has served as Secretary of the Company since 2010. Her current term of office as General Counsel, Senior Vice President and Secretary expires in 2012. Ms. Burke joined the Company in 2008 after serving as General Counsel of privately-held Echo Therapeutics, Inc. from 2004 until its merger with Sontra Medical Corporation to form the Company in September 2007. From 2004 to 2008, she was Director of Legal Affairs at Cato Research Ltd., a global contract research and development organization, and an Associate with Cato BioVentures, a life sciences venture capital firm. Ms. Burke began her career with Devine, Millimet and Branch, a New England law firm, and then moved to Investors Title Company (NASDAQ: ITIC), a holding company engaged in title insurance and investment management services, where she oversaw corporate and securities law matters. She later served as General Counsel of Hemodynamic Therapeutics, a privately-held pharmaceutical company. Ms. Burke received her B.A. from Mount Holyoke College and her J.D. from the College of William and Mary, Marshall-Wythe School of Law. |
Robert Doman |
Mr. Robert F. Doman has been appointed as Director of Echo Therapeutics, Inc., effective March 12, 2013. Most recently, Mr. Doman served as President and Chief Executive Officer of publicly-traded DUSA Pharmaceuticals, Inc., which he joined in 2005. Under his leadership, the company strengthened its IP position, expanded its sales and marketing capabilities and repositioned its products in the marketplace. In 2012, Mr. Doman completed the sale of the company to Sun Pharmaceuticals in a $230 million transaction. From 2000 to 2004, Mr. Doman served as President of Leach Technology Group, the medical electronic device, design, product development and contract manufacturing services division of Leach Holding Corporation, which was sold to Esterline Technologies in 2004. He served as President of Device Product Development of West Pharmaceutical Services from 1999 to 2000. Prior to that, Mr. Doman held marketing and business development positions at the Convatec division of Bristol-Myers Squibb and Critikon, Inc., a Johnson & Johnson company. He earned his Bachelor's degree from Saint Joseph's University. |
Vincent Enright |
Mr. Vincent D. Enright is Independent Director of Echo Therapeutics, Inc., since March 25, 2008. Mr. Enright currently serves as a director of 16 funds, Chairman of the Audit Committee of six funds and as a member of the Audit Committee of 12 funds managed by Gabelli Funds, LLC, and a mutual fund manager, positions he has held since 1991. In July 2011, Mr. Enright became a member of the Board of Directors of The LGL Group, Inc., an electronics manufacturing company, where he serves as a member of the Auditing and Compensation Committees. Mr. Enright served as Senior Vice President and Chief Financial Officer of KeySpan Corporation, a NYSE public utility company, from 1994 to 1998. He previously served as a director of Aphton Corporation, a biopharmaceutical company, from September 2004 through November 2006 (NASDAQ: APHT). Mr. Enright holds a B.S. degree in Accounting from Fordham. |
William Grieco |
Mr. William F. Grieco serves as the Independent Director of Echo Therapeutics Inc. He was appointed to the Board of Directors in February 2011 and his current term expires in 2012. He served as a Director of PHC, Inc., a behavioral health company, from 1997 to 2011. Since 2008, Mr. Grieco has served as the Managing Director of Arcadia Strategies, LLC, a legal and business consulting organization servicing healthcare, science and technology companies. From 2003 to 2008 he served as Senior Vice President and General Counsel of American Science and Engineering, Inc., an x-ray inspection technology company. He served as Senior Vice President and General Counsel of IDX Systems Corporation, a healthcare information technology company. Previously, he was Senior Vice President and General Counsel for Fresenius Medical Care North America, a dialysis products and services company. Prior to that, Mr. Grieco was a partner at Choate, Hall & Stewart, a general service law firm. Mr. Grieco received a B.S. from Boston College, a M.S. in Health Policy and Management from Harvard University and a J.D. from Boston College Law School. |
James Smith |
Mr. James F. Smith serves as the Independent Director of Echo Therapeutics Inc. From October 2007 to December 31, 2011, Mr. Smith served as Vice President and Chief Financial Officer of Orchid Cellmark (NASDAQ: ORCH), an international provider of DNA testing services primarily. From 2004 to 2006, Mr. Smith served as Vice President and Chief Financial Officer of Aphton Corporation (NASDAQ: APHT). |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Patrick Mooney |
1,729,070 |
Christopher Schnittker |
943,000 |
Kimberly Burke |
476,969 |
Robert Doman |
-- |
Vincent Enright |
-- |
William Grieco |
-- |
James Smith |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Patrick Mooney |
0 | 0 |
Christopher Schnittker |
0 | 0 |
Kimberly Burke |
0 | 0 |
Robert Doman |
0 | 0 |
Vincent Enright |
0 | 0 |
William Grieco |
0 | 0 |
James Smith |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
GRIECO WILLIAM F |
4,000 | $0.00 |
ENRIGHT VINCENT D |
4,000 | $0.00 |
DOMAN ROBERT F |
4,000 | $0.00 |
SMITH JAMES FRANCIS |
4,000 | $0.00 |
DOMAN ROBERT F |
15,000 | $0.80 |
GRIECO WILLIAM F |
30,000 | $0.76 |
DOMAN ROBERT F |
20,000 | $0.00 |
GRIECO WILLIAM F |
6,250 | $0.00 |
ENRIGHT VINCENT D |
6,250 | $0.00 |
SMITH JAMES FRANCIS |
6,250 | $0.00 |
SCHNITTKER CHRISTOPHER P |
31,250 | $0.00 |
BURKE KIMBERLY A |
37,500 | $0.00 |
MOONEY PATRICK T |
150,000 | $0.00 |
BURKE KIMBERLY A |
37,500 | $0.00 |
SCHNITTKER CHRISTOPHER P |
31,250 | $0.00 |
GRIECO WILLIAM F |
6,250 | $0.00 |
ENRIGHT VINCENT D |
6,250 | $0.00 |
SMITH JAMES FRANCIS |
6,250 | $0.00 |
SMITH JAMES FRANCIS |
6,400 | $1.47 |
SMITH JAMES FRANCIS |
13,600 | $1.47 |
SMITH JAMES FRANCIS |
6,250 | $0.00 |
GRIECO WILLIAM F |
6,250 | $0.00 |
ENRIGHT VINCENT D |
6,250 | $0.00 |
MOONEY PATRICK T |
625,907 | $0.00 |
SCHNITTKER CHRISTOPHER P |
31,250 | $0.00 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
